247 related articles for article (PubMed ID: 35671095)
1. State-of-the-art imaging in oesophago-gastric cancer.
Withey SJ; Goh V; Foley KG
Br J Radiol; 2022 Sep; 95(1137):20220410. PubMed ID: 35671095
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer.
Blencowe NS; Whistance RN; Strong S; Hotton EJ; Ganesh S; Roach H; Callaway M; Blazeby JM
Br J Cancer; 2013 Sep; 109(6):1445-50. PubMed ID: 23963146
[TBL] [Abstract][Full Text] [Related]
3.
Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
[TBL] [Abstract][Full Text] [Related]
4. PET and PET-CT in esophageal and gastric cancer.
Wieder HA; Krause BJ; Herrmann K
Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929
[TBL] [Abstract][Full Text] [Related]
5. Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.
Bjerring OS; Hess S; Petersen H; Fristrup CW; Lundell L; Mortensen MB
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33688946
[TBL] [Abstract][Full Text] [Related]
6. Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.
Smyth EC; Shah MA
World J Gastroenterol; 2011 Dec; 17(46):5059-74. PubMed ID: 22171140
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
[TBL] [Abstract][Full Text] [Related]
8. The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer.
Rankin S
Cancer Imaging; 2011 Oct; 11 Spec No A(1A):S156-60. PubMed ID: 22186083
[TBL] [Abstract][Full Text] [Related]
9.
Linder G; Korsavidou-Hult N; Bjerner T; Ahlström H; Hedberg J
Clin Radiol; 2019 Sep; 74(9):718-725. PubMed ID: 31221468
[TBL] [Abstract][Full Text] [Related]
10. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
Chowdhury FU; Bradley KM; Gleeson FV
Clin Radiol; 2008 Dec; 63(12):1297-309. PubMed ID: 18996259
[TBL] [Abstract][Full Text] [Related]
12. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
13. Comparison between 18F-FDG PET/MRI and MDCT for the assessment of preoperative staging and resectability of gastric cancer.
Lee DH; Kim SH; Joo I; Hur BY; Han JK
Eur J Radiol; 2016 Jun; 85(6):1085-91. PubMed ID: 27161056
[TBL] [Abstract][Full Text] [Related]
14. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
[TBL] [Abstract][Full Text] [Related]
15. Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review.
Wong WL; Chambers RJ
Abdom Imaging; 2008; 33(2):183-90. PubMed ID: 17619927
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
17. Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer.
Malik V; Johnston C; O'Toole D; Lucey J; O'Farrell N; Claxton Z; Reynolds JV
Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27862622
[TBL] [Abstract][Full Text] [Related]
18. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers.
Malibari N; Hickeson M; Lisbona R
PET Clin; 2015 Jul; 10(3):311-26. PubMed ID: 26099669
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in the staging of esophageal cancer.
Leccisotti L
Rays; 2006; 31(1):9-12. PubMed ID: 16999368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
